CBPO's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.465 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of China Biologic Products Holdings's Forward Dividend Yield %
For the Biotechnology subindustry, China Biologic Products Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biologic Products Holdings's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where China Biologic Products Holdings's Forward Dividend Yield % falls into.
China Biologic Products Holdings Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
China Biologic Products Holdings (NAS:CBPO) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
China Biologic Products Holdings Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of China Biologic Products Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
China Biologic Products Holdings (China Biologic Products Holdings) Business Description
China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CBPO has been successfully added to your